224 related articles for article (PubMed ID: 31061709)
1. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
Gussen H; Hohlstein P; Bartneck M; Warzecha KT; Buendgens L; Luedde T; Trautwein C; Koch A; Tacke F
J Intensive Care; 2019; 7():26. PubMed ID: 31061709
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
Donadello K; Scolletta S; Taccone FS; Covajes C; Santonocito C; Cortes DO; Grazulyte D; Gottin L; Vincent JL
J Crit Care; 2014 Feb; 29(1):144-9. PubMed ID: 24120089
[TBL] [Abstract][Full Text] [Related]
5. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).
Pliyev BK
Mol Cell Biochem; 2009 Jan; 321(1-2):111-22. PubMed ID: 18830568
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
Savva A; Raftogiannis M; Baziaka F; Routsi C; Antonopoulou A; Koutoukas P; Tsaganos T; Kotanidou A; Apostolidou E; Giamarellos-Bourboulis EJ; Dimopoulos G
J Infect; 2011 Nov; 63(5):344-50. PubMed ID: 21839112
[TBL] [Abstract][Full Text] [Related]
7. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
El-Mekkawy MS; Saleh NY; Sonbol AA
Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
[TBL] [Abstract][Full Text] [Related]
8. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Vaschetto R; Navalesi P; Clemente N; Boggio E; Valsecchi S; Olivieri C; Soluri MF; Kroumova V; Fonio P; Dinatale C; Borrè S; Fortina G; Umberto D; Della Corte F; Chiocchetti A
Minerva Anestesiol; 2015 Feb; 81(2):157-65. PubMed ID: 24994498
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Reisinger AC; Niedrist T; Posch F; Hatzl S; Hackl G; Prattes J; Schilcher G; Meißl AM; Raggam RB; Herrmann M; Eller P
Sci Rep; 2021 Sep; 11(1):17476. PubMed ID: 34471146
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Guo H; Zhou LX; Ma H; Liu B; Cheng J; Ma YY; Zhao L
Oncol Lett; 2017 Jul; 14(1):383-389. PubMed ID: 28693180
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis.
Vassiliou AG; Zacharis A; Vrettou CS; Keskinidou C; Jahaj E; Mastora Z; Orfanos SE; Dimopoulou I; Kotanidou A
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626416
[TBL] [Abstract][Full Text] [Related]
15. suPAR as a marker of infection in acute kidney injury - a prospective observational study.
Hall A; Crichton S; Varrier M; Bear DE; Ostermann M
BMC Nephrol; 2018 Aug; 19(1):191. PubMed ID: 30071826
[TBL] [Abstract][Full Text] [Related]
16. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.
Backes Y; van der Sluijs KF; Mackie DP; Tacke F; Koch A; Tenhunen JJ; Schultz MJ
Intensive Care Med; 2012 Sep; 38(9):1418-28. PubMed ID: 22706919
[TBL] [Abstract][Full Text] [Related]
20. The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.
Wrotek A; Jackowska T
Respir Physiol Neurobiol; 2015 Apr; 209():120-3. PubMed ID: 25602915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
